Valsartan improves l-NAME-exacerbated cardiac fibrosis with TGF-β inhibition and apoptosis induction in spontaneously hypertensive rats

Journal of Cardiology

Volumn 52, Issue 3, 2008, Pages 239-246

  Akashiba, Akira ^a   Ono, Hidehiko ^a   Ono, Yuko ^a   Ishimitsu, Toshihiko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blocker; Apoptosis; Cardiac fibrosis; Caspase 3; Hypertension; Nitric oxide; Tissue transforming growth factor ; Valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BETA ACTIN; CASPASE 3; DRINKING WATER; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RNA; TAP WATER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FIBROBLAST; HEART INJURY; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HEART WEIGHT; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LOW DRUG DOSE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; CASPASE 3; FIBROSIS; HYPERTENSION; MALE; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; RATS; RATS, INBRED SHR; RNA; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA; VALINE; VENTRICULAR REMODELING;

EID: 56249085281     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2008.07.018     Document Type: Article

References (31)

1. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens Suppl 23 (2005) S9-S17
2. Ruilope L.M., Rosei E.A., Bakris G.L., Mancia G., Poulter N.R., Taddei S., et al. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 14 (2005) 196-209
3. Ono H., Ono Y., and Frohlich E.D. Nitric oxide synthase inhibition in spontaneously hypertensive rats: systemic, renal, and glomerular hemodynamics. Hypertension 26 (1995) 249-255
4. Ono H., Ono Y., Takanohashi A., Matsuoka H., and Frohlich E.D. Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats. Hypertension 38 (2001) 1300-1306
5. Ono Y., Ono H., Matsuoka H., Fujimori T., and Frohlich E.D. Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 34 (1999) 609-616
6. 1 inhibition in spontaneously hypertensive rats. J Hypertens 22 (2004) 1389-1395
7. 1. Int Heart J 48 (2007) 637-647
8. Fortuño M.A., Ravassa S., Fortuño A., Zalba G., and Díez J. Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension 38 (2001) 1406-1412
9. Díez J. Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens 9 (2007) 546-550
10. Dabek J., Kulach A., Monastyrska-Cup B., and Gasior Z. Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'. Pharmacol Rep 58 (2006) 799-805
11. Ruiz-Ortega M., Rodriguez-Vita J., Sanchez-Lopez E., Carvajal G., and Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74 (2007) 196-206
12. Stegh A.H., and Peter M.E. Apoptosis and caspases. Cardiol Clin 19 (2001) 13-29
13. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376 (1995) 37-43
14. Gibson U.E.M., Heid C.A., and Williams P.M. A novel method for real time quantitative RT-PCR. Genome Res 6 (1996) 995-1001
15. Duncan W.G. Multiple range and multiple F test. Biometrics 11 (1995) 1-42
16. Tharaux P.L., Chatziantoniou C., Fakhouri F., and Dussaule J.C. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 36 (2000) 330-336
17. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (2000) 11-34
18. Williams B. Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 87 (2001) 10C-17C
19. Wahed M.I., Watanabe K., Ma M., Yamaguchi K., Takahashi T., Tachikawa H., et al. Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. Pharmacology 73 (2005) 81-88
20. Jöhren O., Dendorfer A., and Dominiak P. Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res 62 (2004) 460-467
21. Carey R.M. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 45 (2005) 840-844
22. Dimmeler S., Rippmann V., Weiland U., Haendeler J., and Zeiher A.M. Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. Circ Res 81 (1997) 970-976
23. Yamada T., Akishita M., Pollman M.J., Gibbons G.H., Dzau V.J., and Horiuchi M. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis and antagonizes angiotensin II type 1 receptor action: an in vitro gene transfer study. Life Sci 63 (1998) PL289-PL295
24. Abbate A., Bussani R., Biondi-Zoccai G.G., Rossiello R., Silvestri F., Baldi F., et al. Persistent infarct-related artery occlusion is associated with an increased myocardial apoptosis at postmortem examination in humans late after an acute myocardial infarction. Circulation 106 (2002) 1051-1054
25. Koda M., Takemura G., Kanoh M., Hayakawa K., Kawase Y., Maruyama R., et al. Myocytes positive for in situ markers for DNA breaks in human hearts which are hypertrophic, but neither failed nor dilated: a manifestation of cardiac hypertrophy rather than failure. J Pathol 199 (2003) 229-236
26. Takemura G., Ohno M., Hayakawa Y., Misao J., Kanoh M., Ohno A., et al. Role of apoptosis in the disappearance of infiltrated and proliferated interstitial cells after myocardial infarction. Circ Res 82 (1998) 1130-1138
27. Tsutsumi Y., Matsubara H., Ohkubo N., Mori Y., Nozawa Y., Murasawa S., et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 83 (1998) 1035-1046
28. Busche S., Gallinat S., Bohle R.M., Reinecke A., Seebeck J., Franke F., et al. Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study. Am J Pathol 157 (2000) 605-611
29. Gross V., Obst M., and Luft F.C. Insights into angiotensin II receptor function through AT2 receptor knockout mice. Acta Physiol Scand 181 (2004) 487-494
30. Brede M., Roell W., Ritter O., Wiesmann F., Jahns R., Haase A., et al. Cardiac hypertrophy is associated with decreased eNOS expression in angiotensin AT2 receptor-deficient mice. Hypertension 42 (2003) 1177-1182
31. Oishi Y., Ozono R., Yoshizumi M., Akishita M., Horiuchi M., and Oshima T. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life Sci 80 (2006) 82-88